Global Biosimilars Partnering Terms and Agreements 2014 to 2019
The Global Biosimilars Partnering Terms and Agreements 2014 to 2019 report provides an understanding and access to the Biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies.
Trends in Biosimilars partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Biosimilars partnering contract documents
Top Biosimilars deals by value
The Global Biosimilars Partnering Terms and Agreements report provides an understanding and access to the Biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter Biosimilars partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Biosimilars technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains links to online copies of actual Biosimilars deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
For example, analyzing actual company deals and agreements allows assessment of the following:
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What are the precise rights granted or optioned?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
The initial chapters of this report provide an orientation of Biosimilars dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Biosimilars dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading Biosimilars deals since 2014. Deals are listed by headline value, signed by big pharma, most active Biosimilars dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in Biosimilars dealmaking with a brief summary followed by a comprehensive listing of Biosimilars deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of Biosimilars partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 7 provides a comprehensive and detailed review of Biosimilars partnering deals signed and announced since Jan 2014. The chapter is organized by specific Biosimilars technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided organized by Biosimilars partnering company A-Z, deal type definitions and Biosimilars partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Biosimilars partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Biosimilars technologies and products.
Global Biosimilars Partnering Terms and Agreements 2014 to 2019 is intended to provide the reader with an in-depth understanding and access to Biosimilars trends and structure of deals entered into by leading companies worldwide.
Global Biosimilars Partnering Terms and Agreements 2014 to 2019 includes:
Trends in Biosimilars dealmaking in the biopharma industry since 2014
Analysis of Biosimilars deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life Biosimilars deals
Access to over 80 Biosimilars deal records and contract documents where available
The leading Biosimilar deals by value since 2014
Most active Biosimilars dealmakers since 2014
The leading Biosimilars partnering resources
In Global Biosimilars Partnering Terms and Agreements 2014 to 2019, the available contracts are listed by:
Stage of development at signing
Deal component type
Specific therapy and technology target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 1 – Introduction
Chapter 2 – Trends in Biosimilars dealmaking
2.2. Biosimilars partnering over the years
2.3. Most active Biosimilars dealmakers
2.4. Biosimilars partnering by deal type
2.5. Biosimilars partnering by therapy area
2.6. Biosimilars partnering by industry sector
2.7. Deal terms for Biosimilars partnering
2.7.1 Biosimilars partnering headline values
2.7.2 Biosimilars deal upfront payments
2.7.3 Biosimilars deal milestone payments
2.7.4 Biosimilars royalty rates
2.8. The anatomy of an Biosimilars deal
2.8. a. Case study 1: RRD International & Dipexium Pharmaceuticals
2.8.b. Case study 2: Hospira & Cempra Pharmaceutical
2.8.c. Case study 3: Astellas & Optimer Pharmaceuticals
Chapter 3 – Leading Biosimilars deals
3.2. Top Biosimilars deals by value
Chapter 4 – Most active Biosimilars dealmakers
4.2. Most active Biosimilars dealmakers
4.3. Most active Biosimilars partnering company profiles
Chapter 5 – Biosimilars contracts dealmaking directory
5.2. Biosimilars contracts dealmaking directory
Chapter 6 – Biosimilars dealmaking by technology type
Chapter 7 – Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendix 1 – Biosimilars deals by company A-Z
Appendix 2 – Biosimilars deals by stage of development
Appendix 3 – Biosimilars deals by deal type
Appendix 4 – Biosimilars deals by therapy area
Appendix 5 –Deal type definitions
About Wildwood Ventures
Recent report titles from Current Partnering
Table of figures
Figure 1: Biosimilars partnering since 2014
Figure 2: Active Biosimilars dealmaking activity sincce 2014
Figure 3: Biosimilars partnering by deal type since 2014
Figure 4: Biosimilars partnering by disease type since 2014
Figure 5: Biosimilars partnering by industry sector since 2014
Figure 6: Biosimilars deals with a headline value
Figure 7: Biosimilars deals with an upfront value
Figure 8: Biosimilars deals with a milestone value
Figure 9: Biosimilars deals with a royalty rate value
Figure 10: Top Biosimilars deals by value since 2014
Figure 11: Most active Biosimilars dealmakers since 2014
Figure 12: Biosimilars partnering by technology type since 2014
Figure 13: Online partnering resources
Figure 14: Forthcoming partnering events
2021 Global Automated Microbiology Market Assessment--US, Europe, Japan--Supplier Shares and Strategic SWOT Analysis, Segmentation Forecasts for 100 Blood Culture, Identification, Immunodiagnostic, Molecular Dx, Susceptibility and Urine Screening Tests--Latest Technologies and Instrumentation Pipeline, Growth Opportunities, Market Barriers and Threats
This unique report from LeadingMarketResearch.com provides information and analysis not available from any other published source.The report is available by section, and can be customized to specific information needs andView Report
D-ribose is a supplement thats sometimes recommended as a treatment for people with fibromyalgia and chronic fatigue syndrome. In the context of China-US trade war and COVID-19 epidemic, it willView Report
Biosimilars or follow-on-biologics are highly similar versions of reference biologics derived from living organisms such as plants and animals. In the context of China-US trade war and COVID-19 epidemic, itView Report
COVID-19 Outbreak-Global Biosimilars-On-Biologics Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020
The Biosimilars-On-Biologics market revenue was xx.xx Million USD in 2019, and will reach xx.xx Million USD in 2025, with a CAGR of x.x% during 2020-2025.Under COVID-19 outbreak globally, this reportView Report
Fill The Form For Sample Request